In addition to neuroblastoma and WT, MYCN gain or amplification is now emerging as a common aberration associated with adverse outcome in multiple paediatric malignancies, including rhabdomyosarcoma [26] and medulloblastoma [24, 25]. Here, MYCN is linked to rhabdomyosarcoma.